Abstract:Many phosphorescent iridium complexes are potent candidates as photodynamic therapeutic agents. In this work, a series of mixed-ligand phosphorescent iridium complexes (Ir1: [Ir(L-1)(bpy)Cl](PF6)(2); Ir2: [Ir(L-1)(ppy)Cl](PF6); Ir3: [Ir(L-2)(bpy)Cl](PF6)(2); Ir4: [Ir(L-2)(ppy)Cl](P(F)6). L1 = 2,6-bis(2-benzimidazolyl) pyridine; bpy = 2,2'-bipyridine; L-2 = 2,6-bis(1-methyl-benzimidazol-2-yl)pyridine; ppy = 2-phenylpyridine) have been synthesized and characterized. These complexes display high luminescence quantum yields and long phosphorescence lifetimes. All the complexes are resistant to hydrolysis in aqueous solutions, and can produce singlet oxygen (O-1(2)) effectively upon irradiation. Ir1 and Ir2 show pH-sensitive emission properties. Interestingly, higher cellular uptake efficiency is observed for Ir2 and Ir4 with the cyclometalated ppy ligand in human lung adenocarcinoma A549 cells. Ir2 with pH-sensitive emission properties can selectively image lysosomes, and Ir4 can specifically target mitochondria. Both Ir2 and Ir4 exhibit potent photodynamic therapy (PDT) effects, with Ir2 displaying a higher phototoxicity index (PI) especially in A549 cells (PI > 54). Mechanism studies indicate that Ir2 and Ir4 can induce apoptosis through reactive oxygen species (ROS) generation and caspase activation upon visible light (425 nm) irradiation. As expected, Ir2 can damage lysosomes more effectively with a pH-sensitive singlet oxygen (O-1(2)) yield, while Ir4 tends to impair mitochondrial function. Nevertheless, the practical application of Ir2 and Ir4 for PDT may be limited to superficial tumors due to the short excitation wavelength (425 nm). Our study gives insights into the design and anticancer mechanisms of new metal-based PDT anticancer agents.

Phosphorescent Iridium(III) Complexes for Anticancer Applications

Antitumor Activity and Application of Luminescent Iridium (III) Complexes

Design, synthesis, and evaluation of phosphorescent Ir(III) complexes with anticancer activity.

Mixed-ligand iridium(iii) complexes as photodynamic anticancer agents.

Phosphorescent Iridium(iii)-Bis-n-heterocyclic Carbene Complexes As Mitochondria-Targeted Theranostic and Photodynamic Anticancer Agents.

Phosphorescent Metal Complexes As Theranostic Anticancer Agents: Combining Imaging and Therapy in a Single Molecule.

Mitochondria-targeted Phosphorescent Cyclometalated Iridium(iii) Complexes: Synthesis, Characterization, and Anticancer Properties

Delivery of Phosphorescent Anticancer Iridium(III) Complexes by Polydopamine Nanoparticles for Targeted Combined Photothermal-Chemotherapy and Thermal/Photoacoustic/Lifetime Imaging.

Synthesis, Photophysical and Anticancer Properties of Mitochondria-Targeted Phosphorescent Cyclometalated Iridium(iii) N-heterocyclic Carbene Complexes.

Iridium(iii) complexes with five-membered heterocyclic ligands for combined photodynamic therapy and photoactivated chemotherapy.

Recent Advances in Ruthenium(ii) and Iridium(iii) Complexes Containing Nanosystems for Cancer Treatment and Bioimaging

Fluorescent Half-Sandwich Phosphine-Sulfonate Iridium(iii) and Ruthenium(ii) Complexes As Potential Lysosome-Targeted Anticancer Agents

Triphenylamine-appended cyclometallated iridium(III) complexes: Preparation, photophysical properties and application in biology/luminescence imaging.

Zwitterionic Iridium Complexes: Synthesis, Luminescent Properties, and Their Application in Cell Imaging.

Phosphorescent Cyclometalated Iridium(iii) Complexes with Mono‐, Di‐, and Tetranuclear As Two Channel Probes to Light Up the Nuclei of Living Cells

Organometallic ruthenium and iridium phosphorus complexes: Synthesis, cellular imaging, organelle targeting and anticancer applications: Organometallic Complexes Synthesis and Applications

Lysosome-Targeted Phosphine-Imine Half-Sandwich Iridium(III) Anticancer Complexes: Synthesis, Characterization, and Biological Activity

Lysosome-Targeted Cyclometalated Iridium (Iii) Anticancer Complexes Bearing Phosphine-Sulfonate Ligands

Synthesis and Antineoplastic Applications of TPE Appended Organometallic Iridium(III) Complexes.

Iridium(III) coordination compounds based on organophosphorus ancillary ligands showing cytotoxicity against breast cancer cells and Fe(III) luminescent sensing

Acidity-responsive Phosphorescent Metal Complexes for Cancer Imaging and Theranostic Applications